Agree Jake and thanks Buddyboy. When a large acquiring company makes an announcement about a buyout or a partnership with a small biotech the share price of the larger company almost always goes down by at least a few percentage points while the smaller company, or the company who is being partnered with, usually sees a substantial jump in their stock price.

If the market eventually agrees, after studying the investment, then the acquiring company stock price gradually moves back up, and when it is determined that this is most likely a very good investment then the acquiring company’s stock price begins to rise, but not nearly at the level of the Small, partnered biotech..

I’m not saying it is CYDY that caused Citron to take a short position in GSK or even that the reason is another unnamed biotech that they are looking at. But what you are saying Jake is certainly possible.